Clinical Trials Logo

Clinical Trial Summary

The COVID-19 pandemic exacerbates health problems by reducing access to adapted and advanced physical rehabilitation for several people who need rehabilitation services, including the population with myotonic dystrophy type 1 (DM1). The PACE tool, an innovative web tool integrating pragmatic physical activity programs, seems to be an interesting and innovative intervention to counter physical deficiencies of people with DM1, which are unfortunately accentuated by the pandemic, while reducing the risk of COVID-19 exposure. Objectives: 1) Evaluate the feasibility, usability and acceptability of the PACE tool in the DM1 population; 2) Evaluate the effects of the intervention on their physical and cognitive health; and 3) Estimate the cost-effectiveness ratio of this intervention. Method: Sixty people (experimental group = 40 and control group = 20) will participate in this randomized intervention study. Participants in the experimental group will be assigned to one of the 35 physical activity programs adapted to their condition of the PACE tool. The program must be performed on a daily basis for a period of 12 weeks. Physical and cognitive health will be assessed before and after the remote intervention via ZOOM, for all participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05072288
Study type Interventional
Source Université du Québec à Chicoutimi
Contact Anne-Marie Fortin
Phone 418-590-0993
Email [email protected]
Status Recruiting
Phase N/A
Start date August 11, 2021
Completion date October 1, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05027269 - Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Recruiting NCT04835298 - Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1
Completed NCT03589677 - Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life
Recruiting NCT04907162 - Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders